- Home
- EDSA vs CYCN Comparison
EDSA vs CYCN Comparison
Compare EDSA & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- CYCN
- Stock Information
- Founded
- EDSA 2015
- CYCN 2018
- Country
- EDSA Canada
- CYCN United States
- Employees
- EDSA N/A
- CYCN N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- CYCN Health Care
- Exchange
- EDSA Nasdaq
- CYCN Nasdaq
- Market Cap
- EDSA 6.2M
- CYCN 6.5M
- IPO Year
- EDSA N/A
- CYCN N/A
- Fundamental
- Price
- EDSA $2.03
- CYCN $3.04
- Analyst Decision
- EDSA Strong Buy
- CYCN
- Analyst Count
- EDSA 1
- CYCN 0
- Target Price
- EDSA $21.00
- CYCN N/A
- AVG Volume (30 Days)
- EDSA 14.5K
- CYCN 16.1K
- Earning Date
- EDSA 05-14-2025
- CYCN 05-23-2025
- Dividend Yield
- EDSA N/A
- CYCN N/A
- EPS Growth
- EDSA N/A
- CYCN N/A
- EPS
- EDSA N/A
- CYCN N/A
- Revenue
- EDSA N/A
- CYCN $2,081,000.00
- Revenue This Year
- EDSA N/A
- CYCN N/A
- Revenue Next Year
- EDSA N/A
- CYCN N/A
- P/E Ratio
- EDSA N/A
- CYCN N/A
- Revenue Growth
- EDSA N/A
- CYCN N/A
- 52 Week Low
- EDSA $1.55
- CYCN $1.27
- 52 Week High
- EDSA $5.59
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- EDSA 36.85
- CYCN 50.15
- Support Level
- EDSA $1.99
- CYCN $2.83
- Resistance Level
- EDSA $2.14
- CYCN $3.34
- Average True Range (ATR)
- EDSA 0.11
- CYCN 0.32
- MACD
- EDSA -0.03
- CYCN -0.04
- Stochastic Oscillator
- EDSA 21.28
- CYCN 22.68
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.